CA-OMNI-CONVERSION
22.4.2021 06:10:08 CEST | Business Wire | Press release
Today, OMNI Conversion Technologies Inc. (OMNI CT) announced the first sale of its unprecedented waste to hydrogen product. The Larsen and Lam Climate Initiative, a foundation backed by philanthropists Chris Larsen and Lyna Lam, has committed $35 million to bring this ground-breaking technology to production in the fight against climate change. The first commercial plant in production from OMNI CT will use unsorted non-recyclable Municipal Solid Waste (MSW), which is currently disposed of in landfills, to produce negative carbon hydrogen in California.
New technologies are essential in the fight against climate change. While low-cost solar electricity was a dream only a decade ago, its impact today is far-reaching. The Larsen and Lam Climate Initiative investment will accelerate the global adoption of OMNI CT technology.
”Low or zero CO2 fuels are critical to achieving a decarbonized economy. OMNI CT has created a first-of-its-kind product that can have a global and immediate impact. This is why we are excited to work with their team to bring this technology to market in California as our first project from the Larsen and Lam Climate Initiative,” said Chris Larsen, Co-Founder of the Larsen and Lam Climate Initiative and Ripple.
“With surging global interest in hydrogen and biofuels and as the urgency grows around the climate change crisis, it’s an opportune time to be launching our product into the fight against climate change. We’ve spent 15 years and $400 million perfecting it. We’re thrilled to be working with the Larsen and Lam Climate Initiative who not only understand but share our vision for the future,” said Rod Bryden, CEO of OMNI CT.
Professor Daniel Kammen, Chair of the Energy and Resources Group at the University of California, Berkeley, commented that zero-carbon fuels are a critical part of the aggressive path to a clean economy. As California looks to build a vibrant zero-carbon economy, the Omni technology is an exciting addition that will solve multiple problems at once.
The Omni 200™ GPRS™ waste to hydrogen product can produce around 5000 tonnes of negative carbon hydrogen each year, from 200 tonnes a day of unsorted non-recyclable garbage. Hydrogen is produced in the city where it is needed and the garbage is diverted from landfill to OMNI CT and eliminated with no air emissions and nothing left for disposal. Energy in the garbage replaces electricity otherwise required to make green hydrogen. The circular hydrogen produced could operate some 550 city buses running on hydrogen at a cost less than the current cost of using gasoline or diesel.
The purchase was funded and signed on April 21, 2021 with the goal of being in production in California converting Municipal Solid Waste to hydrogen by the end of 2023.
About OMNI CT
OMNI CT is an Ottawa Canada-based company that has developed a proprietary technology by designing, building, testing, and operating a complete commercial demonstration plant from 2007-2014. The patented process converts any solid energetic material into OmniSyngas™ to produce clean green hydrogen, biofuels, synthetic natural gas, chemicals or electricity for the circular economy.
OMNI CT’s robust efficient OMNI200™ GPRS™ is providing a unique solution to achieving decarbonization targets.
The OMNI200™ Gasification & Plasma Refining System (GPRS™)
The OMNI200™ GPRS™ unit is proven at industrial scale. It is a complete integrated system, delivered to site in large modules, rather than stick-built. It receives and converts at a rate of 200 tonnes per day (67,000 tonnes per year) a wide variety and mix of energetic wastes into clean consistent syngas with a predictable heating value and composition. The H2/CO ratio can be tailored to the final application. Multiple units can be readily combined for larger plants.
OmniSyngas™
OmniSyngas™ is a precursor to the production of hydrogen and biofuels. Municipal solid waste has more than 50% biogenic content. This will produce green fuels and avoid methane from sending waste to landfills. Since methane has 25x the GHG effect of CO2, these fuels can be produced with a negative carbon footprint. Further reduction is possible by capturing and storing the CO2 in the syngas.
For additional details on Omni CT’s product: Download Product Description
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421006131/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Okomera Strengthens Its Leadership Team With the Appointment of Marion Ghibaudo as Chief Technology Officer16.9.2026 08:00:00 CEST | Press release
An expert in scaling medical innovations, Marion Ghibaudo joins Okomera as the company advances toward industrial deployment. Okomera, a TechBio company pioneering next-generation cancer care through the development of a proprietary technology platform combining tumor mini-avatars, microfluidics, and AI-powered imaging, today announced the appointment of Marion Ghibaudo as Chief Technology Officer. She will spearhead the company’s technology and innovation strategy and lead the industrial deployment of its integrated hardware, software, and biological platform. Marion Ghibaudo will join Okomera’s Executive Committee and report to CEO Silvère Lucquin. In parallel, Raphaël Tomasi, Okomera’s co-founder and former CTO, transitions to the role of VP Platform, ensuring continuity in the development of the company’s technology platform. Marion’s appointment comes at a key stage in Okomera’s growth as the company advances toward pilot studies, industrial scale-up, and commercialization. Okomer
Galderma’s Restylane® Volyme™ Demonstrates High Effectiveness, Satisfaction and a Robust Safety Profile in Chinese Patients With Temple Hollowing16.9.2026 07:00:00 CEST | Press release
Positive topline results showed that Restylane Volyme (known as Restylane Contour in the U.S.) was highly effective in the correction of moderate-to-severe temple hollowing, with high responder rates maintained through Month 121 Restylane Volyme was well tolerated, with no incidences of granulomas. Patient and investigator satisfaction were also high1 These data support Galderma’s aim to expand the availability of the Restylane portfolio in China – a market undergoing significant expansion, and further strengthen Restylane’s vast clinical evidence base2,3 Galderma (SIX: GALD) today announced positive topline results from a study of Restylane Volyme for the correction of moderate-to-severe temple hollowing in 162 patients in China.1 The study met its primary endpoint, demonstrating the effectiveness and safety of Restylane Volyme versus a no-treatment control, while also achieving high patient and investigator satisfaction.1 These data further reinforce Galderma's ambition to expand its
Nippon Electric Glass’s IR Transmitting Glass “FI-02” Adopted for Heimann Sensor Lens Unit, Enabling a 120° × 68° Field of View16.9.2026 03:00:00 CEST | Press release
Nippon Electric Glass Co., Ltd. (NEG) (TOKYO: 5214), a global leader in specialty glass headquartered in Otsu, Japan, announced that its IR Transmitting Glass (chalcogenide glass) “FI-02” has been adopted for Heimann Sensor GmbH’s wide-angle lens unit for thermal cameras. The lens unit achieves a 120° × 68° field of view, surpassing the previous product’s maximum of 92° × 59°. The adoption marks a significant milestone for FI-02 and showcases how advanced specialty glass can meet the demanding optical and manufacturing requirements of the expanding infrared sensing market. Thermal cameras detect infrared radiation emitted by people or objects and convert it into thermal images. Infrared sensors can detect the locations of people and temperature distributions. They are expected to be used for people detection and monitoring, where privacy considerations are important, and for air-conditioning control, while their use is expanding in healthcare, equipment monitoring, and security. Advanc
Workiva Advances Regulatory Work with AI Innovation15.9.2026 17:00:00 CEST | Press release
Agent Studio anchors AI capabilities unveiled at Amplify 2026 Workiva Inc. (NYSE: WK), a leading, audit-ready platform for trust, transparency, and accountability, unveiled dozens of new product and platform innovations at Amplify 2026, the company’s annual conference attended by thousands of finance, accounting, sustainability, risk, and compliance leaders. Workiva Debuts Agent Studio Workiva introduced Agent Studio, a landmark platform capability that empowers users to quickly build, customize, and deploy AI agents in Workiva's trusted platform. By combining AI reasoning with Workiva's native platform capabilities, enterprise knowledge, and governed workflows, Agent Studio enables users to automate sophisticated manual business processes without writing any code. Organizations can enrich agents with company-specific knowledge and context, tailor them to their own processes, and schedule automations to execute recurring work. “With Agent Studio, we're putting the power to build in the
Study: Heatwaves Increase Cough Urge, Which Salt Aerosols Reduce15.9.2026 15:15:00 CEST | Press release
New Study Indicates Non-Pharmacological Aerosol May Provide Therapeutic Relief for Respiratory Conditions Provoked by the Atmospheric Aridity Inherent to Heatwaves SC Therapeutics, with University North Carolina, Imperial College London, and Boston University, announced publication on Tuesday in Nature Scientific Reports of results from a multi-institutional study indicating that the aridity inherent in heatwaves increases cough hypersensitivity in human airways by collapsing mucus onto cilia in a manner common to chronic respiratory diseases, such as cystic fibrosis, and asthma. The researchers find that alkaline aerosols of magnesium salts reverse mucosal collapse for several hours, and reduce cough hypersensitivity as reflected in placebo-adjusted suppression of daily cough bout rate (59%, p=0.03) and persistence of suppression post treatment for 1 to 3 weeks in a randomized, double-blind, placebo-controlled study of 10 refractory chronic cough patients. “Paris recorded 5,764 excess
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom